Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19

A randomized controlled trial involving a high-risk, unvaccinated population that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir was effective in preventing progression to severe COVID-19. Our objective was to evaluate the effectiveness of nirmatrelvir–ritonavir i...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Canadian Medical Association journal (CMAJ) Ročník 195; číslo 6; s. E220 - E226
Hlavní autori:	Schwartz, Kevin L., Wang, Jun, Tadrous, Mina, Langford, Bradley J., Brown, Kevin A., Daneman, Nick, Leung, Valerie, Gomes, Tara, Friedman, Lindsay, Daley, Peter
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada Elsevier Inc 13.02.2023 CMA Impact Inc CMA Impact, Inc
Predmet:	Admission and discharge Age Analysis Antiretroviral drugs Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs Bias Clinical trials Cohort analysis Cohort Studies Comorbidity Coronaviruses COVID-19 COVID-19 Drug Treatment COVID-19 vaccines Disease susceptibility Dosage and administration Drug dosages Drug interactions Drug therapy, Combination Health insurance Hospital care Hospitalization Hospitals Humans Internal Medicine Pharmacy Polymerase chain reaction Population Protease inhibitors Ritonavir - therapeutic use SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Statistics Testing Vaccination Canada Ontario
ISSN:	0820-3946, 1488-2329, 1488-2329
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!